Voya Investment Management LLC Raises Stock Position in Bruker Corporation $BRKR

Voya Investment Management LLC lifted its stake in Bruker Corporation (NASDAQ:BRKR) by 5.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,821 shares of the medical research company’s stock after buying an additional 7,163 shares during the period. Voya Investment Management LLC owned approximately 0.10% of Bruker worth $6,295,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Captrust Financial Advisors boosted its stake in Bruker by 32.7% in the fourth quarter. Captrust Financial Advisors now owns 5,973 shares of the medical research company’s stock valued at $350,000 after acquiring an additional 1,472 shares in the last quarter. Cetera Investment Advisers increased its position in shares of Bruker by 13.8% during the fourth quarter. Cetera Investment Advisers now owns 23,083 shares of the medical research company’s stock worth $1,353,000 after purchasing an additional 2,799 shares in the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Bruker by 210.3% in the 4th quarter. Quantinno Capital Management LP now owns 12,057 shares of the medical research company’s stock valued at $707,000 after purchasing an additional 8,172 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Bruker by 19.9% in the 4th quarter. ProShare Advisors LLC now owns 9,813 shares of the medical research company’s stock valued at $575,000 after purchasing an additional 1,626 shares during the period. Finally, Snowden Capital Advisors LLC grew its stake in Bruker by 12.8% during the 4th quarter. Snowden Capital Advisors LLC now owns 3,719 shares of the medical research company’s stock worth $218,000 after buying an additional 423 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BRKR has been the subject of a number of research reports. Bank of America reduced their price objective on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the company a “buy” rating in a research report on Monday, August 4th. Barclays lowered their price objective on shares of Bruker from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Monday, August 4th. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Finally, Wells Fargo & Company lowered their price target on Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Tuesday, August 5th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Bruker currently has an average rating of “Hold” and an average target price of $51.30.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.30% of the stock is currently owned by company insiders.

Bruker Price Performance

Shares of BRKR opened at $32.11 on Thursday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock’s 50 day moving average is $35.45 and its two-hundred day moving average is $38.64. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $72.94. The firm has a market capitalization of $4.87 billion, a PE ratio of 61.75, a P/E/G ratio of 4.62 and a beta of 1.21.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same period in the prior year, the business earned $0.52 earnings per share. The firm’s quarterly revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Research analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Tuesday, September 23rd. Bruker’s payout ratio is presently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.